Administration of Dydrogesterone in first trimester of pregnancy will increase the level of PlGF (Placental Growth Factor)

Early placental development can be determined by measuring placental growth factor or Placental growth factor (PlGF) through the mother's blood since the first trimester of pregnancy. The purpose of this study was to determine the effect of supplementation on the development didrogesteron placenta in pregnancy by measuring the levels of PlGF. This study is a randomized double-blind clinical trial (Randomized Controlled Clinical Trial) held at the Antenatal Clinic (ANC) at the General Hospital dr. Zainoel Abidin (RSUZA), Banda Acehto women of reproductive age in the first trimester in RSUZA ANC checkup. Nonprobability sampling sampling with consecutive sampling. In this study there were two groups of women of reproductive age who are not in pairs is given didrogesteron group A while group B received placebo. Measurement of PlGF levels in both groups performed before and after treatment. PlGF levels prior to treatment in Group A 25.95 pg/ml while Group B 40.80 pg/ml. PlGF levels after the measurement results given didrogesteron in Group A for 4 weeks gainedincreasing levels of PlGF is 212.15 pg/ml, whereas in group B were given a placebo for 4 weeks was 89.60 pg/ml. Data analysis was performed using bivariate analysis between supplementation didrogesteron and PlGFlevels using SPSS 17. Analysis of data for comparative analytical numerical information unpaired two groups: Group A: the results of a PlGF levels in pregnant subjects were given didrogesteron and Group B: the results ofa PlGF levels in pregnant patients given placebo. Unpaired t-test results of the two groups showed that the group receiving didrogesteron have elevated levels of PlGF were significantly (p = 0.000 or p 0.05) compared with the placebo group were only given alone. From these results it can be concluded that the administration can trigger didrogesteron PlGF levels in women of reproductive age

Administration of Dydrogesterone in First Trimester of Pregnancy Will Increase the Level of PlGF (Placental Growth Factor)

Early placental development can be determined by measuring placental growth factor or Placental growth factor (PlGF) through the mother's blood since the first trimester of pregnancy. The purpose of this study was to determine the effect of supplementation on the development didrogesteron placenta in pregnancy by measuring the levels of PlGF. This study is a randomized double-blind clinical trial (Randomized Controlled Clinical Trial) held at the Antenatal Clinic (ANC) at the General Hospital dr. Zainoel Abidin (RSUZA), Banda Acehto women of reproductive age in the first trimester in RSUZA ANC checkup. Nonprobability sampling sampling with consecutive sampling. In this study there were two groups of women of reproductive age who are not in pairs is given didrogesteron group A while group B received placebo. Measurement of PlGF levels in both groups performed before and after treatment. PlGF levels prior to treatment in Group A 25.95 pg/ml while Group B 40.80 pg/ml. PlGF levels after the measurement results given didrogesteron in Group A for 4 weeks gainedincreasing levels of PlGF is 212.15 pg/ml, whereas in group B were given a placebo for 4 weeks was 89.60 pg/ml. Data analysis was performed using bivariate analysis between supplementation didrogesteron and PlGFlevels using SPSS 17. Analysis of data for comparative analytical numerical information unpaired two groups: Group A: the results of a PlGF levels in pregnant subjects were given didrogesteron and Group B: the results ofa PlGF levels in pregnant patients given placebo. Unpaired t-test results of the two groups showed that the group receiving didrogesteron have elevated levels of PlGF were significantly (p = 0.000 or p < 0.05) compared with the placebo group were only given alone. From these results it can be concluded that the administration can trigger didrogesteron PlGF levels in women of reproductive age

The Effectiveness of Phalleria Macrocarpa Bioactive Fraction in Alleviating Endometriosis And/or Adenomyosis Related Pain

The overexpression of estrogen receptor-beta (ER-&szlig;) and the cyclooxygenase-2 (COX-2) enzyme coupled with the absence of expression of progesterone receptors (PR) is critical to thepathogenesis of endometriosis and adenomyosis associated pain.&nbsp; DLBS1442, a novel bioactiveextract of Phaleria macrocarpa, exerts its action by downregulating the overexpressed ER-&szlig; andCOX-2 products and up-regulating PR gene expression. This pilot study was conducted to evaluatethe effectiveness of DLBS1442 treatment in alleviating endometriosis- and/or adenomyosis-relatedpain. Ten endometriosis and/or adenomyosis patients were recruited consecutively at YasminClinic Dr. Cipto Mangunkusumo General Hospital in January - March 2013. Pain associated withmenses, including pre-menstrual pain, dysmenorrhea, dyschezia and dysuria, was measuredusing the visual analog scale (VAS) at each of the next three menstrual cycles. Patients reportingone or more pain symptoms with a VAS score = 4 were given 100 mg of DLBS1442 three timesdaily for 12 weeks. VAS score reduction was noted in the first post-treatment menstrual cycle(approximately 5.3 weeks after treatment initiation) and VAS scores continued to decline overthe final two cycles. DLBS1442 was effective in alleviating endometriosis- and/ or adenomyosisrelatedpain, as demonstrated by early pain reduction as evaluated using the VAS

Effect of Conditioned Medium of Umbilical Cord-derived Mesenchymal Stem Cells as A Culture Medium for Human Granulosa Cells: an Experimental Study

Background: The umbilical cord-derived mesenchymal stem cells conditioned medium (UC-MSCs-CM) produces secretomes with anti-apoptotic properties, and has the potential to prevent apoptosis of granulosa cells (GC) during controlled ovarian hyperstimulation. Objective: To observe the effect of UC-MSCs-CM on the interaction between proand anti-apoptotic proteins and the influence of growth differentiation factor 9 (GDF9) production in GC. Materials and Methods: UC-MSCs-CM was collected from umbilical cord stem cell culture on passage 4. GC from 23 women who underwent in vitro fertilization were cultured and exposed to UC-MSCs-CM for 24 hr. Then RNA of the GC was extracted and the mRNA expression of BCL-2 associated X (BAX), survivin and GDF9 were analysed using quantitative real-time PCR. The spent culture media of the GC were collected for measurement of insulin growth factor 1 using ELISA. Results: The expression of BAX was significantly different after UC-MSCs-CM exposure (4.09E-7 vs. 3.74E-7, p = 0.02). No significant changes occurred in survivin, BAX/survivin ratio, and GDF9 expression after UC-MSCs-CM exposure (p gt; 0.05). The IGF-1 level of the CM was significantly higher after the CM was used as a culture medium for GC (2.28 vs. 3.07 ± 1.72, p ≤ 0.001). A significant positive correlation was found between survivin and GDF9 (r = 0.966, p ≤ 0.001). Conclusion: IGF-1 produced by UC-MSCs-CM can work in paracrine Fashion through the IGF receptor, which can inhibit BAX and maintain GDF9 production. Moreover, under the influence of UC-MSCs-CM, GC are also capable of producing IGF-1, which can impact GC through autocrine processes. Key words: Conditioned medium, BAX, Survivin, GDF9, IGF-1

The Effectiveness of Phalleria macrocarpa Bioactive Fraction in Alleviating Endometriosis and/or Adenomyosis Related Pain

The overexpression of estrogen receptor-beta (ER-&szlig;) and the cyclooxygenase-2 (COX-2) enzyme coupled with the absence of expression of progesterone receptors (PR) is critical to thepathogenesis of endometriosis and adenomyosis associated pain.&nbsp; DLBS1442, a novel bioactiveextract of Phaleria macrocarpa, exerts its action by downregulating the overexpressed ER-&szlig; andCOX-2 products and up-regulating PR gene expression. This pilot study was conducted to evaluatethe effectiveness of DLBS1442 treatment in alleviating endometriosis- and/or adenomyosis-relatedpain. Ten endometriosis and/or adenomyosis patients were recruited consecutively at YasminClinic Dr. Cipto Mangunkusumo General Hospital in January - March 2013. Pain associated withmenses, including pre-menstrual pain, dysmenorrhea, dyschezia and dysuria, was measuredusing the visual analog scale (VAS) at each of the next three menstrual cycles. Patients reportingone or more pain symptoms with a VAS score = 4 were given 100 mg of DLBS1442 three timesdaily for 12 weeks. VAS score reduction was noted in the first post-treatment menstrual cycle(approximately 5.3 weeks after treatment initiation) and VAS scores continued to decline overthe final two cycles. DLBS1442 was effective in alleviating endometriosis- and/ or adenomyosisrelatedpain, as demonstrated by early pain reduction as evaluated using the VAS. Keywords: DLBS1442, dysmenorrhea, endometriosis, adenomyosis Efektivitas Ekstrak Bioaktif Phaleria macrocarpa pada Masalah NyeriTerkait Endometriosis dan/ atau Adenomiosis Abstrak Over-ekspresi reseptor estrogen beta (ER-&szlig;) dan enzim siklo-oksigenase-2 (COX-2) akan menekan ekspresi reseptor progesteron (PR) di endometrium; hal tersebut penting dalampatogenesis endometriosis dan adenomiosis. DLBS 1442, ekstrak bioaktif Phaleria macrocarpa,bekerja dengan menekan over-ekspresi ER-&szlig; dan COX-2 serta meningkatkan regulasi ekspresigen PR. Studi awal dilakukan untuk mengevaluasi efektivitas pengobatan DLBS1442 padamasalah nyeri terkait endometriosis dan/ atau adenomiosis. Sepuluh penderita endometriosis dan/atau adenomiosis di klinik Yasmin RSCM pada bulan Januari - Maret 2013 yang memiliki keluhannyeri diikutsertakan dalam penelitian ini. Dilakukan penilaian skor visual analog scale (VAS) untukkeluhan nyeri pre-menstruasi, dismenorea, diskezia dan disuria setiap 3 siklus menstruasi. Pasienyang memiliki keluhan satu atau dua gejala nyeri dengan skor VAS &gt; 4 diberikan DLBS1442sebanyak 3 x 100 mg sehari selama 12 minggu. Penurunan skor VAS diperoleh pada siklus pertamamenstruasi pascapengobatan (sekitar 5,3 minggu setelah inisiasi pengobatan) dan penurunanskor VAS terus berlanjut setelah melewati 2 siklus terakhir pengobatan. DLBS 1442 efektif dalammengatasi masalah nyeri pada endometriosis dan/ atau&nbsp;&nbsp; adenomiosis. Kata Kunci: DLBS 1442, dismenorea, endometriosis, adenomiosi